At a glance
| Chemical family | An antineoplastic (chemotherapy) drug — an anthracycline (brand name Adriamycin) |
| CAS number | 23214-92-8 |
| Carcinogen status | IARC Group 2A — probably carcinogenic to humans (sufficient animal evidence, strong genotoxicity); also linked to secondary leukaemias in treated patients |
| Where you encounter it | Only in a home where someone is being treated: excreted in urine and other fluids (often reddish-tinted), depositing on toilet/bathroom surfaces, bedding and laundry |
| Sleep micro-environment relevance | A household caregiver- and laundry-hygiene concern — contaminated bedding and surfaces, not the mattress — for a limited period after each dose |
| Activated carbon capture | Not relevant — a surface/laundry-residue issue managed by gloves, separate laundering and cleaning, not air filtration |
What it is
Doxorubicin is an anthracycline — a class of chemotherapy drugs derived originally from Streptomyces bacteria — and one of oncology's workhorses, used against breast cancer, lymphomas, leukaemias, sarcomas and many solid tumours. It kills cancer cells by intercalating into DNA and poisoning topoisomerase II, the enzyme that untangles DNA during cell division. Patients and nurses know it as the "red devil," both for its vivid red colour and for the harshness of its side effects, including cardiotoxicity. As with everything in this family, it is first and foremost an important medicine.
Its place in this Atlas rests on a clear classification. The International Agency for Research on Cancer evaluated doxorubicin (under the name adriamycin) and placed it in Group 2A — probably carcinogenic to humans: there was sufficient evidence in experimental animals, where it produced mammary tumours in rats and was active across other tumour systems, and it is strongly genotoxic, even though the direct human evidence was inadequate at the time. Peer-reviewed — IARC Monographs Suppl. 7, Adriamycin The same property that makes it lethal to tumour cells — DNA damage — is what underlies that classification.
How it relates to the bedroom
The household route: excretion onto surfaces and bedding
Doxorubicin reaches the sleep environment through the patient's excreta, and it is unusually easy to picture because it is so visibly coloured — it can tint urine and other fluids reddish for a day or two after a dose. Hospital monitoring repeatedly finds antineoplastic drugs across patient areas and getting into staff: most nurses studied carried measurable internal antineoplastic-drug contamination, doxorubicin among the drugs detected, some of it from skin contact with contaminated surfaces rather than direct handling. Peer-reviewed — Villa et al. 2021
And the bedroom-specific finding holds for doxorubicin as for the platinum drugs: among the tasks that most strongly predicted picking up these agents, changing the sheets or making the bed of a treated patient stood out. Peer-reviewed — Villa et al. 2023 In a home, that task belongs to the family caregiver — and the reddish staining doxorubicin can leave is a built-in cue for what to handle with care.
Keeping it in proportion
The calibration is the same as for the rest of the family. Doxorubicin is a genotoxic, IARC Group 2A drug, so precautions are warranted — but documented third-party exposures are low-level traces, and the right response is sensible hygiene, not alarm. Inferred — household third-party exposure is low-level; precaution follows the ALARA principle The drug is doing essential work for the patient; the caregiver's job is to keep their own incidental contact low during the short window after each dose.
What the research says
- IARC Group 2A. Probably carcinogenic to humans — sufficient animal evidence (mammary tumours in rats), strongly genotoxic. Peer-reviewed — IARC Suppl. 7, Adriamycin
- Excreted and surface-deposited. Detected among antineoplastic drugs on patient-area surfaces and in nurses. Peer-reviewed — Villa et al. 2021
- Bedding is a real route. Sheet-changing/bed-making strongly associated with internal contamination. Peer-reviewed — Villa et al. 2023
- Visibly traceable. Reddish tinting of fluids is a practical cue for what to handle carefully. Inferred — well-known clinical property of doxorubicin
What helps reduce it
Follow your care team's home-chemo precautions. Generally for about a week after each dose. Inferred — standard home-chemotherapy caregiver guidance
Glove up and launder separately. Disposable gloves for soiled linens and fluids; wash contaminated bedding apart from other laundry with an extra rinse. Peer-reviewed — Villa et al. 2023
Manage the bathroom. Close the lid before flushing and clean surfaces — the documented hot spots. Peer-reviewed — Villa et al. 2021
What does NOT help
- Replacing the mattress. The drug is a transient excreted residue, not a bedding ingredient; hygiene and laundering address it. Inferred
- Panic over the red staining. The colour is a useful cue, not a sign of danger in itself; the response is gloves and separate laundering, not fear. Inferred
Open research questions
- The real magnitude of any health risk to home caregivers from low-level contact with excreted anthracyclines. Speculation
- How long doxorubicin and its coloured metabolites remain detectable on home bedding and surfaces after a dose. Speculation
Citations
- IARC Monographs, Supplement 7 (1987). Adriamycin (Doxorubicin). International Agency for Research on Cancer. Group 2A, probably carcinogenic to humans; sufficient animal evidence (mammary tumours in rats), strongly genotoxic. inchem.org Peer-reviewed
- Villa A, et al. (2021). Nurses' internal contamination by antineoplastic drugs in hospital centers. Int. Arch. Occup. Environ. Health. 60.8% of nurses internally contaminated, doxorubicin among drugs detected; some from skin contact with contaminated surfaces. Via Consensus. Reference record Peer-reviewed
- Villa A, et al. (2023). Factors associated with internal contamination of nurses by antineoplastic drugs. Int. J. Hyg. Environ. Health. Changing sheets / making the bed of a treated patient strongly associated with internal contamination (OR ~10). Via Consensus. Reference record Peer-reviewed
Frequently asked questions
What is doxorubicin?
Doxorubicin (brand name Adriamycin, often called the "red devil" for its bright red colour and harsh side effects) is an anthracycline chemotherapy drug used against breast cancer, lymphomas, leukaemias and many solid tumours. It works by wedging into DNA and poisoning the enzyme topoisomerase II, which makes it a powerful cancer killer. Like every drug in this family, it is a valuable medicine; it appears in a bedroom atlas only because of what happens after a dose.
Is doxorubicin a carcinogen?
Yes. The International Agency for Research on Cancer classifies doxorubicin (adriamycin) as Group 2A, probably carcinogenic to humans, based on sufficient evidence in animals — it caused mammary tumours in rats and was active in other tumour systems — together with strong genotoxicity. It is also linked to secondary leukaemias in treated patients. This is the basis for handling it, and a caregiver's exposure to excreta, with care.
Why does it matter in the bedroom?
Because patients excrete it for days, and it is vividly traceable — doxorubicin can tint urine and other fluids reddish after a dose. Hospital monitoring finds antineoplastic drugs, doxorubicin among them, on patient-area surfaces and getting into staff through skin contact. The single strongest bedroom-specific finding is that changing the sheets or making the bed of a treated patient is one of the best predictors of picking these drugs up — in a home, that is the family caregiver.
What should a caregiver do?
Follow the home-chemotherapy precautions from the care team, generally for about a week after each dose. Wear disposable gloves when handling soiled bedding, clothing or body fluids; launder contaminated linens separately with an extra rinse; close the toilet lid before flushing and clean bathroom surfaces; and wash hands afterward. The reddish staining doxorubicin can cause is a useful visual cue for what to handle carefully. The goal is to keep a caregiver's incidental exposure as low as reasonably achievable.
Related compounds
Embr is a sleep environment company researching and addressing the chemistry of the bedroom. Research and product development in progress. This page is informational and is not medical advice; follow your care team's guidance.
Last reviewed 2026-06-27. If you find a factual error, contact us.